pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$VIRVir Biotechnology, Inc.

$VIR9.2100-5.73%
San Francisco, CA, USupdated 6h ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
5
marketed
0
phase 3
3
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(5)

pipeline depth5 products
Phase 1: 2Phase 3: 3
2Phase 13Phase 3
Phase 3
elebsiran
Hepatitis D
Phase 3
elebsiran + tobevibart
Hepatitis D
Phase 3
tobevibart
Hepatitis D
Phase 1
VIR-5500
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase 1
VIR-5525
Adenocarcinoma

📅 Upcoming

Nov 4, 2026
earnings
$VIR9.2100-5.73%
in 3mo
Vir Biotechnology, Inc. earnings
Vir Biotechnology, Inc.
→

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infectioncompletedn=244
  • phase1Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancerrecruitingn=390
  • phase2Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infectioncompletedn=84
  • phase1Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumorsrecruitingn=450
  • phase3A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infectionactive not recruitingn=124
  • phase3A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtiderecruitingn=150
  • phase2A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infectioncompletedn=33
  • phase2A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infectionactive not recruitingn=100
more trials →

Insider activity

source: SEC Form 4

open-market buys + sells

  • Apr 6, 26SELLDe Backer Marianne· President and CEO72,559 sh @ $9.16−$664K↗
  • Apr 1, 26SELLSATO VICKI L· director22,000 sh @ $9.07−$200K↗
  • Mar 23, 26SELLSabatini Brent· SVP, Chief Accounting Officer7,711 sh @ $9.12−$70K↗
  • Mar 2, 26SELLSATO VICKI L· director21,800 sh @ $9.50−$207K↗
  • Mar 2, 26SELLSATO VICKI L· director200 sh @ $9.98−$2K↗
  • Feb 25, 26SELLde Verneuil Vanina· EVP, General Counsel, Corp Sec13,700 sh @ $9.82−$135K↗
  • Feb 25, 26SELLEisner Mark· EVP and Chief Medical Officer1,889 sh @ $9.82−$19K↗
  • Feb 24, 26SELLSATO VICKI L· director42,177 sh @ $9.75−$411K↗
  • Feb 24, 26SELLDe Backer Marianne· Chief Executive Officer14,762 sh @ $9.53−$141K↗
  • Feb 24, 26SELLde Verneuil Vanina· EVP, General Counsel, Corp Sec3,117 sh @ $9.53−$30K↗
  • Feb 24, 26SELLO'Byrne Jason· EVP & Chief Financial Officer1,634 sh @ $9.53−$16K↗
  • Feb 24, 26SELLEisner Mark· EVP and Chief Medical Officer1,616 sh @ $9.53−$15K↗
  • Feb 24, 26SELLSabatini Brent· SVP, Chief Accounting Officer1,430 sh @ $9.53−$14K↗
  • Feb 24, 26SELLSATO VICKI L· director200 sh @ $10.26−$2K↗
  • Feb 23, 26SELLDe Backer Marianne· Chief Executive Officer19,039 sh @ $7.45−$142K↗
  • Feb 23, 26SELLde Verneuil Vanina· EVP, General Counsel, Corp Sec4,445 sh @ $7.45−$33K↗
  • Feb 23, 26SELLO'Byrne Jason· EVP & Chief Financial Officer2,089 sh @ $7.45−$16K↗
  • Feb 23, 26SELLEisner Mark· EVP and Chief Medical Officer2,089 sh @ $7.45−$16K↗
  • Feb 23, 26SELLSabatini Brent· SVP, Chief Accounting Officer1,829 sh @ $7.45−$14K↗
routine RSU / option mechanics (1)
  • Mar 20, 26otherO'Byrne Jason · EVP & Chief Financial Officer2,500 sh
🐶 Hiring Signal
next earnings Nov 4, 2026
No open roles indexed yet — view Vir Biotechnology, Inc. jobs →

News

no news has mentioned this company yet
identifiers
ticker
$VIR
SEC CIK
0001706431
country
US
source
sec_tickers
top tags
Infectious Disease3Oncology2NSCLC1
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 29m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?